Futura Medical, a United Kingdom-based developer, has introduced a new medication called Sildenafil Cream 3.6, aimed at addressing safety concerns related to erectile dysfunction. The cream is currently undergoing clinical trials, with hopes of advancing to Phase 2b by the end of 2019.
With a focus on men's sexual health, Dare Bioscience Inc. and Strategic Science Technologies LLC are collaborating on the development of Sildenafil Cream 3.6, which targets endothelial dysfunction to improve blood flow and overall sexual function.
Generated from the website